Novo Nordisk Stocks Rise 5.65% While Higher Guidance Meets Diverging Profit Measures

What happened

Novo Nordisk raised its annual outlook for adjusted sales and operating profit to a range of 2% decline to 2% growth at constant exchange rates. Its U.S. depositary shares rose 5.65% to $42.46 at 10:35 a.m. ET on November 4. Third-quarter adjusted operating profit increased, while reported operating profit fell after noncash impairments.

Confirmed

Global impact / market context

The higher outlook may support expectations for sales and operating profit, but its range still allows for a decline. The gap between rising adjusted profit and falling reported profit matters because impairments reduced the reported result, leaving investors to judge underlying performance against accounting losses.

Analyst inference

The article describes a mixed picture: Wegovy pill revenue rose from the preceding quarter, while reported operating profit fell after impairments. It also cites a price-to-earnings ratio of 10.38, which compares share price with earnings, and says the valuation measure warrants closer attention.

Analyst inference

What to watch

1. Check whether Novo Nordisk meets its revised annual ranges for adjusted sales and operating profit; results near the lower end would leave the outlook’s downside risk visible. Analyst inference
2. Watch whether Wegovy pill revenue continues to grow in later reports, since the article says it rose 53% from the preceding quarter and beat expectations. Analyst inference
3. Track reported operating profit and any further noncash impairments, which are accounting reductions not involving cash and contributed to the divergence from adjusted profit. Analyst inference

Evidence

• gurufocus.com